Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Dow
Baxter
McKinsey
AstraZeneca

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,213,487


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,213,487 protect, and when does it expire?

Patent 10,213,487 protects BAQSIMI and is included in one NDA.

This patent has forty-seven patent family members in thirty-six countries.

Summary for Patent: 10,213,487
Title:Nasal powder formulation for treatment of hypoglycemia
Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
Inventor(s): Mantripragada; Sankaram (Windsor, CO), Piche; Claude A. (Verdun, CA), Van Betsbrugge; Jo Jan Filip (Laval, CA)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:15/545,332
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Delivery;

Drugs Protected by US Patent 10,213,487

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,213,487

PCT Information
PCT FiledFebruary 16, 2016PCT Application Number:PCT/US2016/018003
PCT Publication Date:August 25, 2016PCT Publication Number: WO2016/133863

International Family Members for US Patent 10,213,487

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016220235 ⤷  Free Forever Trial
Australia 2021203035 ⤷  Free Forever Trial
Brazil 112017014994 ⤷  Free Forever Trial
Canada 2975562 ⤷  Free Forever Trial
Chile 2017002031 ⤷  Free Forever Trial
China 107278154 ⤷  Free Forever Trial
Colombia 2017008148 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.